Uterine rupture during second trimester termination of pregnancy using mifepristone and a prostaglandin.
Phillips
K
K
Department of Gynaecology, Glasgow Royal Infirmary, Scotland, UK.
Berry
C
C
Mathers
A M
AM
D000020:Abortifacient Agents, Nonsteroidal / Q000009:adverse effects*; D000021:Abortifacient Agents, Steroidal / Q000009:adverse effects*; D000032:Abortion, Therapeutic / Q000009:adverse effects*; D000328:Adult; D005260:Female; D006801:Humans; D015735:Mifepristone / Q000009:adverse effects*; D016595:Misoprostol / Q000009:adverse effects*; D011247:Pregnancy; D011262:Pregnancy Trimester, Second; D014597:Uterine Rupture / Q000139:chemically induced*
D000020:Abortifacient Agents, Nonsteroidal; D000021:Abortifacient Agents, Steroidal; D016595:Misoprostol; D015735:Mifepristone